24/7 Market News Snapshot 18 November, 2024 – HCW Biologics Inc. Common Stock (NASDAQ:HCWB)

November 18, 2024

DENVER, Colo., 18 November, 2024 (247marketnews.com) – (NASDAQ:HCWB) are discussed in this article.
HCW Biologics Inc. has captured significant investor attention recently, with its stock price experiencing a remarkable increase of 123.35% in pre-market trading, climbing to $0.658 from the prior close of $0.295. This surge has been accompanied by impressive trading volumes exceeding 5.53 million shares, indicating strong market enthusiasm for the biotech firm. The recent spike in HCWB’s shares reflects growing optimism surrounding the company’s potential in the rapidly evolving biopharmaceutical landscape.

In a stride towards enhancing its innovative capabilities, HCW Biologics has also announced a strategic partnership with WY Biotech Co., Ltd. This worldwide exclusive License, Research, and Co-Development Agreement focuses on advancing one of HCW Biologics’ proprietary preclinical molecules, developed through its cutting-edge drug discovery platform. As part of the collaboration, HCW Biologics is set to receive an upfront payment of $7 million, alongside potential milestone payments and double-digit royalties on future product sales. The agreement further includes a provision that allows HCW Biologics to reclaim development rights in key territories following the completion of Phase 1 clinical trials.

This partnership highlights HCW Biologics’ dedication to addressing age-related diseases associated with chronic inflammation, utilizing its extensive expertise in T cell and natural killer (NK) cell immunology. Designed to enhance anti-tumor responses effectively, the product candidate has demonstrated promising efficacy in preclinical trials while circumventing common side effects linked to conventional therapies.

Dr. Hing C. Wong, Founder and CEO, emphasized the importance of this collaboration, noting the mutual recognition of the potential impact of their transformative treatments on patient health. As HCW Biologics continues to innovate within the immunotherapy sector, this partnership is positioned to pave the way for new therapeutic options aimed at improving healthspan and advancing healthcare solutions.

Related news for (HCWB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.